Leveraging big data of immune checkpoint blockade response identifies novel potential targets
Author:
Publisher
Elsevier BV
Subject
Oncology,Hematology
Reference86 articles.
1. The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy;Havel;Nat Rev Cancer,2019
2. Resistance mechanisms to immune-checkpoint blockade in cancer: tumor-intrinsic and -extrinsic factors;Pitt;Immunity,2016
3. Primary, adaptive, and acquired resistance to cancer immunotherapy;Sharma;Cell,2017
4. Intratumoral heterogeneity in cancer progression and response to immunotherapy;Vitale;Nat Med,2021
5. Microenvironmental regulation of tumor progression and metastasis;Quail;Nat Med,2013
Cited by 33 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. A Phase II, Open-Label, Randomized Trial of Durvalumab With Olaparib or Cediranib in Patients With Mismatch Repair—Proficient Colorectal or Pancreatic Cancer;Clinical Colorectal Cancer;2024-09
2. Combined Transcriptome and Circulating Tumor DNA Longitudinal Biomarker Analysis Associates With Clinical Outcomes in Advanced Solid Tumors Treated With Pembrolizumab;JCO Precision Oncology;2024-08
3. Novel molecular subtypes of METex14 non-small cell lung cancer with distinct biological and clinical significance;npj Precision Oncology;2024-07-26
4. Transcriptome Deconvolution Reveals Absence of Cancer Cell Expression Signature in Immune Checkpoint Blockade Response;Cancer Research Communications;2024-06-26
5. LORIS robustly predicts patient outcomes with immune checkpoint blockade therapy using common clinical, pathologic and genomic features;Nature Cancer;2024-06-03
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3